Loading...
Please wait, while we are loading the content...
Similar Documents
The efficacy and safety of intravesical gemcitabine vs Bacille Calmette-Guérin for adjuvant treatment of non-muscle invasive bladder cancer: a meta-analysis
| Content Provider | Scilit |
|---|---|
| Author | Ye, Ziqi Chen, Jie Hong, Yun Xin, Wenxiu Yang, Si Rao, Yuefeng |
| Copyright Year | 2018 |
| Abstract | The efficacy and safety of intravesical gemcitabine vs Bacille Calmette-Guerin for adjuvant treatment of non-muscle invasive bladder cancer: a meta-analysis Ziqi Ye,1,* Jie Chen,2,* Yun Hong,1 Wenxiu Xin,3 Si Yang,1 Yuefeng Rao1 1Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People’s Republic of China; 2The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People’s Republic of China; 3Laboratory of Clinical Pharmacy, Zhejiang Cancer Hospital, Hangzhou, People’s Republic of China *These authors contributed equally to this work Objective: Several studies have compared the safety and efficacy of intravesical gemcitabine (Gem) with Bacille Calmette-Guérin (BCG) for non-muscle invasive bladder cancer. However, the results are not consistent. We carried out a meta-analysis to provide a more comprehensive analysis of the efficacy and safety of these 2 drugs. Methods: We searched PubMed, EMBASE, Cochrane Library, Clinical Trials.gov, and reference lists. Randomized controlled trials and retrospective controlled trials comparing intravesical Gem and BCG in adjuvant therapy for non-muscle invasive bladder cancer published in English were included in this study. The strength of association was weighed by pooled risk ratio (RR) with 95% CIs. Sensitivity analysis was performed to examine whether the findings of the meta-analysis were robust. Results: We analyzed 386 subjects from 5 pooled trials. Compared with BCG, intravesical Gem had lower incidence of dysuria (overall RR =0.31, 95% CI: 0.16, 0.61, I2=0%, p=0.001) and hematuria (overall RR =0.27, 95% CI: 0.11, 0.71, I2=0%, p=0.008). There were no statistical differences in risk of recurrence, progression, incidence of fever, and any adverse events between intravesical Gem and BCG therapy (p>0.05). No publication bias was found. Conclusion: This meta-analysis suggests that intravesical Gem may have similar efficacy and lower incidence of dysuria and hematuria compared with BCG. Nevertheless, we recommend additional high-quality randomized controlled trials to confirm these results. Keywords: intravesical therapy, non-muscle invasive bladder cancer, NMIBC, gemcitabine, Bacille Calmette-Guérin, meta-analysis |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087023/pdf https://www.dovepress.com/getfile.php?fileID=43572 |
| Ending Page | 4649 |
| Page Count | 9 |
| Starting Page | 4641 |
| ISSN | 11786930 |
| DOI | 10.2147/ott.s170477 |
| Journal | OncoTargets and therapy |
| Volume Number | 11 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2018-08-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Oncotargets and Therapy Integrative and Complementary Medicine Bacille Calmette-guérin Nmibc Gemcitabine Intravesical Therapy Meta-analysis Non-muscle Invasive Bladder Cancer |
| Content Type | Text |
| Resource Type | Article |
| Subject | Pharmacology (medical) Oncology |
